Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Barinthus Biotherapeutics's Days Sales Outstanding or its related term are showing as below:
During the past 7 years, Barinthus Biotherapeutics's highest Days Sales Outstanding was 2661.04. The lowest was 23.95. And the median was 211.74.
STU:2AB's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.89 * Ranked among companies with meaningful Days Sales Outstanding only.
Barinthus Biotherapeutics's Days Sales Outstanding
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Barinthus Biotherapeutics (STU:2AB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Barinthus Biotherapeutics Days Sales Outstanding Related Terms
Barinthus Biotherapeutics Days Sales Outstanding Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics Days Sales Outstanding Chart
STU:2AB vs VTGN, PSTV, PVCT: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Days Sales Outstanding falls into.
Barinthus Biotherapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a Days Sales Outstanding of 0.00 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Barinthus Biotherapeutics and its competitors. Over the past decade, Barinthus Biotherapeutics' Days Sales Outstanding has ranged from 23.95 to 2,661.04. According to the industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 836 companies in the Biotechnology industry.
Is Barinthus Biotherapeutics' Days Sales Outstanding too high?
Barinthus Biotherapeutics' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 23.95 to a high of 2,661.04. Based on the distribution chart, Barinthus Biotherapeutics ranks #999999 out of 836 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Days Sales Outstanding compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 836 companies for Days Sales Outstanding. This places Barinthus Biotherapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 68.89. Historically, Barinthus Biotherapeutics' own Days Sales Outstanding has ranged from 23.95 to 2,661.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.89, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Days Sales Outstanding of 0.00. The stock's GF Value™ is €0.98, compared to a current price of €0.53 — trading 46.4% below its estimated fair value. The current Days Sales Outstanding is 0.00. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Days Sales Outstanding is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.53 is trading 46.4% below its estimated GF Value™ of €0.98.
Key valuation signals for STU:2AB:
Days Sales Outstanding: 0.00
GF Value™: €0.98 vs. price of €0.53 (46.4% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
